Edition:
India

IP Group PLC (IPO.L)

IPO.L on London Stock Exchange

130.00GBp
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
130.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
683,491
52-wk High
158.40
52-wk Low
99.80

Summary

Name Age Since Current Position

Mike Humphrey

65 2015 Non-Executive Independent Chairman of the Board

Alan Aubrey

55 2006 Chief Executive Officer, Executive Director

Greg Smith

38 2011 Chief Financial Officer, Executive Director

David Baynes

53 2014 Chief Operating Officer, Executive Director

Michael Townend

54 2011 Chief Investment Officer, Executive Director

Angela Leach

2008 Company Secretary

David Begg

2018 Senior Independent Director

Jonathan Brooks

61 2011 Non-Executive Independent Director

Lynn Gladden

55 2014 Non-Executive Independent Director

Elaine Sullivan

56 2015 Non-Executive Independent Director

Biographies

Name Description

Mike Humphrey

Mr. Mike Humphrey is Non-Executive Independent Chairman of the Board of IP Group plc., effective March 24, 2015. He is the former CEO of Croda International plc. He was appointed to the Board of Croda in 1995 and became Group Chief Executive at the beginning of 1999. He joined Croda in 1969 as a management trainee and was appointed Managing Director of Croda Singapore in 1988, Croda Application Chemicals in 1990 and Croda Chemicals in 1991. He retired from Croda at the end of 2011.

Alan Aubrey

Mr. Alan John Aubrey is Chief Executive Officer, Executive Director of IP Group Plc. He co-founded Techtran Group Limited in 2002 and was its CEO when the business was acquired by IP Group in January 2005. Previously he was a partner in KPMG where he specialised in corporate finance advice to technology-based fast growth businesses and has an experience in helping them raise money and prepare for sale or flotation. Alan joined the Board of IP Group in January 2005, becoming Chief Executive on 1 January 2006 and has overall responsibility for the operational management of the Group. He is also a chairman of the Department for Business, Innovation & Skills (“BIS”) audit and risk committee.

Greg Smith

Mr. Greg Smith ACA., is Chief Financial Officer, Executive Director of IP Group plc., since June 3, 2011. He joined IP Group in January 2008 and was appointed Chief Financial Officer in June 2011. Previously Greg spent three years at Tarchon Capital Management, a multi-billion dollar fund of hedge funds business where he had day-to-day responsibility for building and managing the operations and accounting team as well as external operational due diligence on investee hedge funds. Prior to Tarchon, Greg spent four years in KPMG’s London Financial Services practice working with asset management, insurance and banking clients. Greg is Chartered Accountant and holds a degree in mathematics from the University of Warwick.

David Baynes

Mr. David Baynes is Chief Operating Officer, Director of IP Group PLC. David, who was previously a Chief Executive Officer of Fusion IP plc ("Fusion IP"), was appointed to IP Group's Board upon completion of the Group's acquisition of Fusion IP last month.

Michael Townend

Mr. Michael Charles Nettleton Townend is Chief Investment Officer, Executive Director of IP Group Plc. He was formerly managing director within the European Equities business of Lehman Brothers with responsibility for equity sales to hedge funds. Mike has over 17 years of experience in all aspects of equity capital markets. Mike was appointed a director of IP Group in March 2007.

Angela Leach

David Begg

Jonathan Brooks

Mr. Jonathan Brooks is Non-Executive Independent Director of IP Group plc., since 31 August 2011. He was the chief financial officer of ARM Holdings plc from 1995 until 2002 where he was responsible for finance, investor relations, legal and IT, and where he managed the dual-listed IPO process of ARM on the London Stock Exchange and Nasdaq in 1998. He is a non-executive director of Aveva Group plc, a provider of engineering data and design IT systems, and chairman of Nasdaq-listed Xyratex Ltd, a provider of data storage systems. He joined IP Group’s Board in 2011 and is also Chairman of the Group’s Audit Committee.

Lynn Gladden

Professor Lynn Gladden,CBE., is Non-Executive Independent Director of IP Group PLC. She is Pro-Vice-Chancellor for Research for the University of Cambridge, the Shell Professor of Chemical Engineering and the former Head of the Department of Chemical Engineering and Biotechnology. Professor Gladden serves as a Director of Cambridge Enterprise Limited, is a former member of the Council of the Engineering and Physical Sciences Research Council (EPSRC) and, in 2013, she was appointed to the Shell Science Council. She was Science Advisor to Unilever from 1998 - 2006 and a Senior Consultant to Physical & Engineering Sciences at Unilever from 2006-2008. She is a Fellow of the Royal Society, the Royal Academy of Engineering, the Institution of Chemical Engineers, the Royal Society of Chemistry and the Institute of Physics and is a chartered engineer and chartered chemist. Professor Gladden leads the activities at the Magnetic Resonance Research Centre at the University of Cambridge and has a particular interest in applying magnetic resonance imaging techniques in the fields of heterogeneous catalysis and multi-phase transport in porous media. She is a Fellow of Trinity College. She was awarded the 2014 Bakerian Lecture of the Royal Society and, in 2001, the Tilden lectureship and silver medal of the Royal Society of Chemistry. In 1996, she was awarded a Miller Visiting Professorship at the University of California, Berkeley and she received the Beilby Medal and Prize from the Royal Society of Chemistry in 1995. In 2013, Professor Gladden was awarded an Honorary Doctorate of Science from the University of Bristol and in 2009 she was awarded a CBE for services to chemical engineering following an OBE for services to chemistry in 2001.

Elaine Sullivan

Dr. Elaine Sullivan is Non-Executive Independent Director of IP Group Plc., with effect from 30 July 2015. Dr Sullivan has over 25 years of international experience working in the pharmaceutical industry and was a member of the senior management teams in R&D at Eli Lilly and AstraZeneca. She has developed new molecules in therapy areas including virology, cancer, ophthalmology, respiratory and inflammation. In 2015, she founded a specialist oncology company, Carrick Therapeutics, and holds the position of Chief Executive. From 2011 to 2015, Dr Sullivan was Vice President Global External Research & Development in the US for Eli Lilly, where she led a global workforce delivering access to business critical external innovation. Global External R&D included the search and evaluation function and Chorus, the virtual early phase drug development arm. She was also a member of the Investment Committees of Lilly Ventures and Lilly Asian Ventures and a member of the Steering Committees of Lilly's Capital Fund Partners. Dr Sullivan spent over 15 years at AstraZeneca, where she held a number of roles including Vice President, Science & Technology. During this period, she identified and established novel drug-hunting approaches from target to delivery of proof of concept, which successfully reduced compound attrition in the clinic and significantly decreased the time to deliver new molecules. She also held the position of Vice President, R&D New Opportunities, establishing and leading the first virtual Therapy Area in AstraZeneca. New Opportunities pinpointed new disease areas and future healthcare trends, created new therapeutic applications for multiple molecular entities and advanced them into the clinic. Dr Sullivan has a BSc (Hons) in Molecular Biology from the University of Glasgow and a PhD in Molecular Virology from the University of Edinburgh. In June 2015, Dr Sullivan was appointed to the Supervisory Board of Evotec AG, a drug discovery solutions company.

Basic Compensation

Name Fiscal Year Total

Mike Humphrey

153,000

Alan Aubrey

265,000

Greg Smith

260,000

David Baynes

296,000

Michael Townend

284,000

Angela Leach

--

David Begg

--

Jonathan Brooks

55,000

Lynn Gladden

40,000

Elaine Sullivan

40,000
As Of  31 Dec 2016